Today is World Bronchiectasis Day.

Bronchiectasis is a long-term condition that affects the airways in your lungs. If you have bronchiectasis, your airways are wider and become inflamed.

To find out more visit asthmaandlung.org.uk/conditions/bronchiectasis

Absolutely delighted and privileged to have been appointed as a new group leader at @thecimr.bsky.social this week. The Dickens lab will be up and running later this year, continuing to understand mechanisms of disease in genetic forms of pulmonary fibrosis.

The New England Journal of Medicine Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis A Research Summary based on Chalmers JD et al. | 10.1056/NEJMoa2411664 | Published on April 24, 2025 Visual representations of the patients in the trial and the treatments they were assigned. Read the full Research Summary at NEJM.org.

In the ASPEN phase 3 trial involving patients with noncystic fibrosis bronchiectasis, the rate of pulmonary exacerbations over a 52-week period was lower with brensocatib (10 mg or 25 mg per day) than with placebo. Full trial results and Research Summary: nej.md/4lBHwUr

#MedSky #PulmSky

A pleural-ity of pulmonologists?

Placet!

Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial Benralizumab can be used as a treatment of acute eosinophilic exacerbations and achieves better outcomes than the current standard of care with prednisolone alone. These results offer a new way of tre...

Fantastic to see the ABRA trial published and the traction it’s getting in global news. Paradigm shifting!

www.thelancet.com/journals/lan...